Response Genetics Inc. (RGDXQ)

[califax]

Business Summary

http://finance.yahoo.com/q/pr?s=RGDX

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe.

It develops genetic tests that measure predictive factors for therapy response in tumor tissue samples.

The company offers tests for non-small cell lung cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, and breast cancer patients? tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, and ResponseDX: and Tissue of Origin test suites.

It also provides HER2 mutation detection, cKIT mutation detection, MET gene amplification, and UGT1A1 SNP tests, including ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2.

In addition, the company focuses on the development of various diagnostic tests for predicting therapy response and determining the diagnosis and prognosis of solid tumors in cancer patients.

It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and cancer care centers through its sales force.